BioDelivery Sciences International, Inc.  

(Public, NASDAQ:BDSI)   Watch this stock  
Find more results for Mark Patton´┐Ż
-0.15 (-4.03%)
After Hours: 3.57 0.00 (0.00%)
Feb 9, 4:06PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.35 - 3.70
52 week 3.04 - 15.50
Open 3.62
Vol / Avg. 1.50M/1.07M
Mkt cap 187.51M
P/E     -
Div/yield     -
EPS -1.26
Shares 52.67M
Beta 2.41
Inst. own 88%
Mar 13, 2016
BioDelivery Sciences International Inc at ROTH Conference Add to calendar
Mar 10, 2016
Q4 2015 BioDelivery Sciences International Inc Earnings Release - Tentative - 9:30AM EST - Add to calendar
Mar 10, 2016
Q4 2015 BioDelivery Sciences International Inc Earnings Call - Tentative Add to calendar
Mar 8, 2016
BioDelivery Sciences International Inc at Cowen Health Care Conference - 8:00AM EST - Add to calendar
Feb 25, 2016
BioDelivery Sciences International Inc Analyst and Investor Day - 2:30PM EST - Add to calendar
Dec 2, 2015
BioDelivery Sciences International Inc at Piper Jaffray Healthcare Conference
Nov 18, 2015
BioDelivery Sciences International Inc at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -1654.98% -139.22%
Operating margin -1591.26% -99.48%
EBITD margin - -96.66%
Return on average assets -104.22% -85.17%
Return on average equity -300.20% -202.39%
Employees 29 -
CDP Score - -


4131 Parklake Avenue, Suite 225
United States - Map
+1-919-5829050 (Phone)
+1-919-5829051 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate, BELBUCA utilize its BEMA technology.

Officers and directors

Frank E. O'Donnell Jr. MD Executive Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Mark A. Sirgo Pharm.D President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Ernest R. De Paolantonio CPA Chief Financial Officer, Treasurer, Secretary
Age: 62
Bio & Compensation  - Reuters
Niraj Vasisht Senior Vice President, Chief Technology Officer
Bio & Compensation  - Reuters
Albert J. Medwar Senior Vice President - Corporate and Business Development
Bio & Compensation  - Reuters
Stephana E. Patton Ph.D., J.D. Vice President, General Counsel
Bio & Compensation  - Reuters
Sarah DeRossett Vice President - Clinical Research and Medical Affairs
Bio & Compensation  - Reuters
Joseph Lockhart Vice President - Manufacturing and Supply Chain
Bio & Compensation  - Reuters
William B. Stone Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Charles J. Bramlage Independent Director
Age: 54
Bio & Compensation  - Reuters